Halozyme Therapeutics announced that former chief financial officer David Ramsay will return as interim CFO, effective March 23, 2026, following the departure of the company’s previous CFO.
Ramsay previously led Halozyme’s finance function from 2003‑2009 and again from 2013‑2015, steering the company through a period of rapid growth and its transition to a public biopharmaceutical business. His deep familiarity with Halozyme’s ENHANZE® drug‑delivery platform, which enables subcutaneous administration of biologics, and his track record in capital markets and investor relations position him to maintain financial stability during the search for a permanent replacement.
The interim role carries a monthly salary of $50,000 and an equity grant, underscoring the company’s confidence in Ramsay’s ability to manage its financial strategy while a full‑time CFO is sought.
Halozyme’s most recent financial results underscore the importance of experienced financial leadership. For the full year 2025, the company reported record total revenue of $1.4 billion, up 38% year‑over‑year, driven largely by a 52% increase in royalty revenue to $867.8 million from ENHANZE‑enabled products such as DARZALEX SC, VYVGART Hytrulo and PHESGO. Guidance for 2026 projects total revenue of $1.71 billion to $1.81 billion, royalty revenue of $1.13 billion to $1.17 billion, and adjusted EBITDA of $1.1 billion to $1.2 billion, reflecting continued momentum in the company’s core technology portfolio.
Dr. Helen Torley, President and CEO, said, “His deep understanding of Halozyme, combined with his exceptional capital markets expertise, investor expertise and credibility, and his longstanding record of financial leadership, makes him an invaluable partner as we advance our strategic priorities. David has made a lasting impact on Halozyme’s evolution, and we are fortunate to welcome him back into a role where his experience and leadership will be immediately impactful.” A search firm has been engaged to identify a permanent CFO, with the company indicating that the search is well underway but no specific timeline has been disclosed.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.